New shot aims to clear hepatitis b virus in Long-Term patients
NCT ID NCT07179653
First seen Oct 01, 2025 · Last updated May 02, 2026 · Updated 27 times
Summary
This study tests an experimental injection called TVAX-008 in 48 adults with chronic hepatitis B (a long-term liver infection). The goal is to see if it can safely clear the hepatitis B surface antigen (HBsAg) from the blood, which would indicate strong virus control. Participants either receive TVAX-008 or a placebo, and the study is double-blind (neither patients nor doctors know who gets which). This is a Phase 2 trial, meaning it's still early and focuses on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NanFang Hospital
Guangzhou, Guangdong, 20000, China
Conditions
Explore the condition pages connected to this study.